Renal denervation and CD161a immune ablation prevent cholinergic hypertension and renal sodium retention.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
Read More Add to Saved list
  • Additional Information
    • Source:
      Publisher: American Physiological Society Country of Publication: United States NLM ID: 100901228 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1522-1539 (Electronic) Linking ISSN: 03636135 NLM ISO Abbreviation: Am J Physiol Heart Circ Physiol Subsets: MEDLINE
    • Publication Information:
      Original Publication: Bethesda, Md. : American Physiological Society,
    • Subject Terms:
      Blood Pressure* ; Kidney*/blood supply ; Kidney*/drug effects ; Kidney*/immunology ; Nicotine* ; Nicotinic Agonists* ; Renal Reabsorption* ; Sympathectomy, Chemical*; Antibodies, Monoclonal/*administration & dosage ; Hypertension/*prevention & control ; Macrophages/*drug effects ; NK Cell Lectin-Like Receptor Subfamily B/*antagonists & inhibitors ; Phenol/*administration & dosage ; Renal Artery/*innervation ; Sodium/*urine; Animals ; Disease Models, Animal ; Hypertension/chemically induced ; Hypertension/immunology ; Hypertension/physiopathology ; Inflammation Mediators/immunology ; Macrophages/immunology ; Male ; NK Cell Lectin-Like Receptor Subfamily B/immunology ; Rats, Inbred SHR ; Solute Carrier Family 12, Member 1/metabolism
    • Abstract:
      Cholinergic receptor activation leads to premature development of hypertension and infiltration of proinflammatory CD161a + /CD68 + M1 macrophages into the renal medulla. Renal inflammation is implicated in renal sodium retention and the development of hypertension. Renal denervation is known to decrease renal inflammation. The objective of this study was to determine the role of CD161a + /CD68 + macrophages and renal sympathetic nerves in cholinergic-hypertension and renal sodium retention. Bilateral renal nerve denervation (RND) and immune ablation of CD161a + immune cells were performed in young prehypertensive spontaneously hypertensive rat (SHR) followed by infusion of either saline or nicotine (15 mg·kg -1 ·day -1 ) for 2 wk. Immune ablation was conducted by injection of unconjugated azide-free antibody targeting rat CD161a + . Blood pressure was monitored by tail cuff plethysmography. Tissues were harvested at the end of infusion. Nicotine induced premature hypertension, renal expression of the sodium-potassium chloride cotransporter (NKCC2), increases in renal sodium retention, and infiltration of CD161a + /CD68 + macrophages into the renal medulla. All of these effects were abrogated by RND and ablation of CD161a + immune cells. Cholinergic activation of CD161a + immune cells with nicotine leads to the premature development of hypertension in SHR. The effects of renal sympathetic nerves on chemotaxis of CD161a + macrophages to the renal medulla, increased renal expression of NKCC2, and renal sodium retention contribute to cholinergic hypertension. The CD161a + immune cells are necessary and essential for this prohypertensive nicotine-mediated inflammatory response. NEW & NOTEWORTHY This is the first study that describes a novel integrative physiological interaction between the adrenergic, cholinergic, and renal systems in the development of hypertension, describing data for the role of each in a genetic model of essential hypertension. Noteworthy findings include the prevention of nicotine-mediated hypertension following successful immune ablation of CD161a + immune cells and the necessary role these cells play in the overexpression of the sodium-potassium-chloride cotransporter (NKCC2) in the renal medulla and renal sodium retention. Renal infiltration of these cells is demonstrated to be dependent on the presence of renal adrenergic innervation. These data offer a fertile ground of therapeutic potential for the treatment of hypertension as well as open the door for further investigation into the mechanism involved in inflammation-mediated renal sodium transporter expression. Taken together, these findings suggest immune therapy, renal denervation, and, possibly, other new molecular targets as having a potential role in the development and maintenance of essential hypertension.
    • References:
      Curr Opin Nephrol Hypertens. 2002 Mar;11(2):197-200. (PMID: 11856913)
      J Leukoc Biol. 2002 Jun;71(6):941-9. (PMID: 12050178)
      Immunol Rev. 2001 Dec;184:38-44. (PMID: 12086320)
      Am J Pathol. 1958 Jul-Aug;34(4):685-715. (PMID: 13559400)
      JAMA. 2003 Dec 10;290(22):2945-51. (PMID: 14665655)
      J Pharmacol Exp Ther. 2004 Dec;311(3):1052-61. (PMID: 15340004)
      J Immunol. 2006 Feb 15;176(4):2397-406. (PMID: 16455998)
      J Immunol. 2006 Jun 15;176(12):7412-20. (PMID: 16751386)
      Hypertension. 2007 Jun;49(6):1351-7. (PMID: 17438304)
      J Exp Med. 2007 Oct 1;204(10):2449-60. (PMID: 17875676)
      Am J Surg. 2007 Nov;194(5):652-8. (PMID: 17936429)
      Hypertension. 2007 Dec;50(6):1069-76. (PMID: 17938380)
      Clin Exp Pharmacol Physiol. 2007 Dec;34(12):1307-12. (PMID: 17973873)
      J Am Soc Nephrol. 2008 Jul;19(7):1371-8. (PMID: 18400940)
      Lancet. 2009 Apr 11;373(9671):1275-81. (PMID: 19332353)
      Proc Natl Acad Sci U S A. 2010 Feb 16;107(7):3006-11. (PMID: 20133607)
      Lancet. 2010 Dec 4;376(9756):1903-9. (PMID: 21093036)
      Exp Physiol. 2011 Jul;96(7):611-22. (PMID: 21551268)
      Front Immunol. 2011 Aug 30;2:36. (PMID: 22566826)
      Circ Res. 2012 Oct 12;111(9):1190-7. (PMID: 22904093)
      Blood. 2013 Apr 4;121(14):2647-58. (PMID: 23355538)
      Lancet. 2014 Feb 15;383(9917):622-9. (PMID: 24210779)
      Nat Rev Nephrol. 2014 Jun;10(6):305-13. (PMID: 24733118)
      J Immunol. 2014 Oct 1;193(7):3366-77. (PMID: 25172498)
      Hypertension. 1989 Apr;13(4):327-33. (PMID: 2564373)
      Circ Res. 2015 Aug 28;117(6):547-57. (PMID: 26156232)
      J Am Heart Assoc. 2015 Sep 21;4(9):e001802. (PMID: 26391130)
      Hypertension. 2016 Jul;68(1):167-74. (PMID: 27141060)
      Circ Res. 2016 Oct 28;119(10):1101-1115. (PMID: 27660287)
      Oncotarget. 2016 Oct 18;7(42):67828-67840. (PMID: 27661131)
      Hypertension. 2016 Dec;68(6):1415-1423. (PMID: 27698066)
      Hypertension. 2017 Feb;69(2):323-331. (PMID: 27956575)
      Lancet. 2017 Nov 11;390(10108):2160-2170. (PMID: 28859944)
      Am J Physiol Heart Circ Physiol. 2018 Apr 1;314(4):H724-H732. (PMID: 29351459)
      Am J Physiol Regul Integr Comp Physiol. 2018 Jun 1;314(6):R883-R891. (PMID: 29513561)
      Front Immunol. 2018 Apr 09;9:486. (PMID: 29686665)
      Lancet. 2018 Jun 9;391(10137):2346-2355. (PMID: 29803589)
      Am J Physiol Heart Circ Physiol. 2018 Aug 1;315(2):H303-H313. (PMID: 30028200)
      Kidney Int. 1979 Jan;15(1):33-7. (PMID: 491394)
      J Clin Invest. 1980 Nov;66(5):971-8. (PMID: 7000828)
      Acta Pathol Microbiol Scand A. 1976 Nov;84(6):523-8. (PMID: 998251)
    • Grant Information:
      K08 HL119588 United States HL NHLBI NIH HHS; L30 HL134111 United States HL NHLBI NIH HHS; P30 DK054759 United States DK NIDDK NIH HHS
    • Contributed Indexing:
      Keywords: CD161; CD68; adrenergic; cholinergic; hypertension; inflammation; innate immunity; macrophage; nicotine; renal; renal denervation
    • Accession Number:
      0 (Antibodies, Monoclonal)
      0 (Inflammation Mediators)
      0 (Klrb1a protein, mouse)
      0 (NK Cell Lectin-Like Receptor Subfamily B)
      0 (Nicotinic Agonists)
      0 (Slc12a1 protein, rat)
      0 (Solute Carrier Family 12, Member 1)
      339NCG44TV (Phenol)
      6M3C89ZY6R (Nicotine)
      9NEZ333N27 (Sodium)
    • Publication Date:
      Date Created: 20190608 Date Completed: 20200323 Latest Revision: 20201228
    • Publication Date:
      20231215
    • Accession Number:
      PMC6766722
    • Accession Number:
      10.1152/ajpheart.00234.2019
    • Accession Number:
      31172810